source
- Boehringer Ingelheim to seek approval for obesity injection survodutide after trial shows no added cardiovascular riskBoehringer Ingelheim announced it will file for regulatory approval of its investigational GLP-1 based obesity injection, survodutide, in the coming year. The move follows a phase 3 trial that dem…
- Compass Pathways to file FDA approval for psilocybin depression therapy within weeksCompass Pathways announced it will complete its FDA filing for the psilocybin‑based depression treatment COMP360 in the next two weeks. The company expects the rolling submission to enable a drug…